10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM TO

Commission File Number: 001-33185

MEDICINOVA, INC.

(Exact name of registrant as specified in its charter)


Delaware		33-0927979
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification No.)

4275 Executive Square, Suite 300 La Jolla, CA		92037
(Address of Principal Executive Offices)		(Zip Code)

(858) 373-1500

(Registrant’s Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:


Common Stock, $0.001 par value	MNOV	The Nasdaq Stock Market LLC
(Title of each class)	(Trading symbol(s))	(Name of each exchange on which registered)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “accelerated filer”, “large accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☐	Accelerated filer	☐

Non-accelerated filer	☒	Smaller reporting company	☒

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November 13, 2024, the registrant had 49,046,246 shares of Common Stock ($0.001 par value) outstanding.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q, in particular "Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations," and the information incorporated by reference herein contains “forward-looking statements”. The forward-looking statements are contained principally in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” but are also contained elsewhere in this report. Forward-looking statements include all statements that are not historical facts and, in some cases, can be identified by terms such as "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would" or the negative version of these words and similar expressions.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including those described in "Risk Factors" and elsewhere in this report. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our beliefs and assumptions only as of the date of this report. Considering the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. You should read this report completely and with the understanding that our actual future results may be materially different from what we expect.

The following factors are among those that may cause actual results to differ materially from our forward-looking statements:

•

Inability to raise additional capital if needed;

•

Inability to generate revenues from product sales to continue business operations;

•

Inability to develop and commercialize our product candidates;

•

Failure or delay in completing clinical trials or obtaining Food and Drug Administration or foreign regulatory approval for our product candidates in a timely manner;

•

Unsuccessful clinical trials stemming from clinical trial designs, failure to enroll a sufficient number of patients, undesirable side effects and other safety concerns;

•

Inability to demonstrate sufficient efficacy of product candidates;

•

Reliance on the success of our MN-166 (ibudilast) and MN-001 (tipelukast) product candidates;

•

Delays in commencement or completion of clinical trials or suspension or termination of clinical trials;

•

Loss of our licensed rights to develop and commercialize a product candidate as a result of the termination of the underlying licensing agreement;

•

Competitors may develop products rendering our product candidates obsolete and noncompetitive;

•

Inability to successfully attract partners and enter into collaborations on acceptable terms;

•

Dependence on third parties to conduct clinical trials and to manufacture product candidates;

•

Dependence on third parties to market and distribute products;

•

Our product candidates, if approved, may not gain market acceptance or obtain adequate coverage for third party reimbursement;

•

Disputes or other developments concerning our intellectual property rights;

•

Actual and anticipated fluctuations in our quarterly or annual operating results;

•

Price and volume fluctuations in the overall stock markets;

•

Litigation or public concern about the safety of our potential products;

•

International trade or foreign exchange restrictions, increased tariffs, foreign currency exchange;

•

High quality material for our products may become difficult to obtain or expensive;

•

Strict government regulations on our business;

•

Regulations governing the production or marketing of our product candidates;

•

Loss of, or inability to attract, key personnel; and

•

Economic, political, foreign exchange and other risks associated with international operations.

•

The widespread outbreak of an illness or any other communicable disease, such as COVID-19, which has led to lead key employees becoming ill for a period of time;

Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to “MediciNova,” “we,” “us” and “our” refer to MediciNova, Inc.

MEDICINOVA, INC.

TABLE OF CONTENTS


PART I. FINANCIAL INFORMATION		5

ITEM 1.	CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)	5
ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	17
ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	22
ITEM 4.	CONTROLS AND PROCEDURES	22

PART II. OTHER INFORMATION		23

ITEM 1.	LEGAL PROCEEDINGS	23
ITEM 1A.	RISK FACTORS	23
ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	23
ITEM 3.	DEFAULTS UPON SENIOR SECURITIES	23
ITEM 4.	MINE SAFETY DISCLOSURES	23
ITEM 5.	OTHER INFORMATION	23
ITEM 6.	EXHIBITS	24

SIGNATURES		25

PART I. FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS.

MEDICINOVA, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)


	September 30,			December 31,
	2024			2023
Assets
Current assets:
Cash and cash equivalents	$	42,280,618		$	50,999,442
Prepaid expenses and other current assets		984,860			174,938
Total current assets		43,265,478			51,174,380
Goodwill		9,600,240			9,600,240
In-process research and development		4,800,000			4,800,000
Property and equipment, net		30,813			45,800
Right-of-use asset		403,894			575,406
Other non-current assets		18,996			74,151
Total assets	$	58,119,421		$	66,269,977
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	708,203		$	1,003,937
Accrued liabilities and other current liabilities		1,686,739			2,059,238
Operating lease liability		201,976			215,926
Total current liabilities		2,596,918			3,279,101
Deferred tax liability		201,792			201,792
Other non-current liabilities		255,150			410,660
Total liabilities		3,053,860			3,891,553
Commitments and contingencies (Note 4)
Stockholders’ equity:
Common stock, $0.001 par value; 100,000,000 shares authorized at September 30, 2024 and December 31, 2023; 49,046,246 and 49,046,246 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively		49,046			49,046
Additional paid-in capital		479,076,908			478,149,161
Accumulated other comprehensive loss		(123,803	)		(118,090	)
Accumulated deficit		(423,936,590	)		(415,701,693	)
Total stockholders’ equity		55,065,561			62,378,424
Total liabilities and stockholders' equity	$	58,119,421		$	66,269,977

See accompanying notes.

MEDICINOVA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)


	Three months ended						Nine months ended
	September 30,						September 30,
	2024			2023			2024			2023
Revenues	$	—		$	1,000,000		$	—		$	1,000,000
Operating expenses:
Research, development and patents		1,859,400			794,706			5,287,318			4,007,117
General and administrative		1,449,728			1,352,182			4,204,299			4,403,044
Total operating expenses		3,309,128			2,146,888			9,491,617			8,410,161
Operating loss		(3,309,128	)		(1,146,888	)		(9,491,617	)		(7,410,161	)
Interest income		447,847			437,934			1,280,708			1,398,400
Other income (expense), net		9,102			(14,153	)		(23,988	)		(500,670	)
Net loss	$	(2,852,179	)	$	(723,107	)	$	(8,234,897	)	$	(6,512,431	)
Basic and diluted net loss per common share	$	(0.06	)	$	(0.01	)	$	(0.17	)	$	(0.13	)
Shares used to compute basic and diluted net loss per common share		49,046,246			49,046,246			49,046,246			49,046,246
Net loss	$	(2,852,179	)	$	(723,107	)	$	(8,234,897	)	$	(6,512,431	)
Other comprehensive loss, net of tax:
Foreign currency translation adjustments		7,724			(2,712	)		(5,713	)		(8,467	)
Comprehensive loss	$	(2,844,455	)	$	(725,819	)	$	(8,240,610	)	$	(6,520,898	)

See accompanying notes.

MEDICINOVA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)


	Nine Months Ended September 30, 2024
	Common stock				Additional paid-in		Accumulated other comprehensive			Accumulated			Total stockholders’
	Shares		Amount		capital		loss			deficit			equity
Balance at December 31, 2023		49,046,246	$	49,046	$	478,149,161	$	(118,090	)	$	(415,701,693	)	$	62,378,424
Share-based compensation	—		—			215,430	—			—				215,430
Net loss	—		—		—		—				(2,754,518	)		(2,754,518	)
Foreign currency translation adjustments	—		—		—			(8,892	)	—				(8,892	)
Balance at March 31, 2024		49,046,246		49,046		478,364,591		(126,982	)		(418,456,211	)		59,830,444
Share-based compensation		—		—		207,455		—			—			207,455
Net loss		—		—		—		—			(2,628,200	)		(2,628,200	)
Foreign currency translation adjustments		—		—		—		(4,545	)		—			(4,545	)
Balance at June 30, 2024		49,046,246		49,046		478,572,046		(131,527	)		(421,084,411	)		57,405,154
Share-based compensation		—		—		504,862		—			—			504,862
Net loss		—		—		—		—			(2,852,179	)		(2,852,179	)
Foreign currency translation adjustments		—		—		—		7,724			—			7,724
Balance at September 30, 2024		49,046,246	$	49,046	$	479,076,908	$	(123,803	)	$	(423,936,590	)	$	55,065,561


	Nine Months Ended September 30, 2023
	Common stock				Additional paid-in		Accumulated other comprehensive			Accumulated			Total stockholders’
	Shares		Amount		capital		loss			deficit			equity
Balance at December 31, 2022		49,046,246	$	49,046	$	477,438,451	$	(115,285	)	$	(407,130,177	)	$	70,242,035
Share-based compensation	—		—			403,263	—			—				403,263
Net loss	—		—		—		—				(2,917,504	)		(2,917,504	)
Foreign currency translation adjustments	—		—		—			(1,542	)	—				(1,542	)
Balance at March 31, 2023		49,046,246		49,046		477,841,714		(116,827	)		(410,047,681	)		67,726,252
Share-based compensation		—		—		325,710		—			—			325,710
Net loss		—		—		—		—			(2,871,820	)		(2,871,820	)
Foreign currency translation adjustments		—		—		—		(4,213	)		—			(4,213	)
Balance at June 30, 2023		49,046,246		49,046		478,167,424		(121,040	)		(412,919,501	)		65,175,929
Share-based compensation		—		—		219,142		—			—			219,142
Net loss		—		—		—		—			(723,107	)		(723,107	)
Foreign currency translation adjustments		—		—		—		(2,712	)		—			(2,712	)
Balance at September 30, 2023		49,046,246	$	49,046	$	478,386,566	$	(123,752	)	$	(413,642,608	)	$	64,669,252

See accompanying notes.

MEDICINOVA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)


	Nine months ended
	September 30,
	2024			2023
Operating activities:
Net loss	$	(8,234,897	)	$	(6,512,431	)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash stock-based compensation		927,747			948,115
Depreciation and amortization		15,900			14,803
Loss on disposal of investments		—			102,513
(Gain) loss on disposal of property and equipment		(199	)		371
Change in carrying amount of right-of-use asset		129,179			146,205
Changes in assets and liabilities:
Accounts receivable		—			(1,000,000	)
Prepaid expenses and other assets		(755,820	)		(27,478	)
Accounts payable, accrued liabilities and other liabilities		(665,592	)		(457,675	)
Operating lease liability		(127,550	)		(146,401	)
Net cash used in operating activities		(8,711,232	)		(6,931,978	)
Investing activities:
Proceeds from disposal of investments		—			39,929,015
Proceeds from sale of property and equipment		199			—
Acquisitions of property and equipment		(897	)		(21,321	)
Net cash (used in) provided by investing activities		(698	)		39,907,694
Effect of exchange rate changes on cash and cash equivalents		(6,894	)		26,152
Net change in cash and cash equivalents		(8,718,824	)		33,001,868
Cash and cash equivalents, beginning of period		50,999,442

SEC Form 10-Q filed by Medicinova Inc